Tianqing Chu

机构：East China University of Science and Technology, Shanghai Chest Hospital · ORCID：0000-0002-1383-0383

发表论文 73 篇 · 总被引 1024 次 · h-index 14

代表论文

• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer (2024 · Thoracic Cancer · 被引 19)
• A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer (2023 · Lung Cancer · 被引 14)
• Tumor immune dysfunction and exclusion evaluation and chemoimmunotherapy response prediction in lung adenocarcinoma using pathomic-based approach (2024 · Chinese Medical Journal · 被引 9)
• Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment (2024 · Frontiers in Immunology · 被引 9)
• Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study (2024 · BMC Cancer · 被引 8)
• Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study (2023 · Translational Lung Cancer Research · 被引 7)